Impact of short-term neoadjuvant hormonal treatment on neuroendocrine differentiation in prostate carcinoma.
- Author:
Gui-zhong LI
1
;
Li ZENG
;
Jun ZHANG
;
Yi-ming YUAN
;
Xin-yu YANG
;
Jing-hua WANG
;
Yan-qun NA
;
Ying-lu GUO
Author Information
- Publication Type:Journal Article
- MeSH: Aged; Androgen Antagonists; therapeutic use; Antineoplastic Agents, Hormonal; therapeutic use; Chromogranin A; Chromogranins; analysis; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neurosecretory Systems; pathology; Prostatic Neoplasms; drug therapy; pathology; Serotonin; analysis
- From: Chinese Journal of Oncology 2003;25(5):493-495
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo study the impact of short-term neoadjuvant hormonal treatment on neuroendocrine (NE) differentiation and the relation of NE differentiation and tumor regression.
METHODSThe radical prostatectomy specimens and the biopsy specimens of the same 18 patients with prostate cancer were compared. The effect of hormonal treatment on NE-differentiation was evaluated by specific antibodies against chromogranin A (ChA) and serotonin (5-HT).
RESULTSThe ChA-positive cell count was 3.2 x 10(-5)/microm(2) [(0-5.7) x 10(-5)/microm(2)] before hormonal treatment and 2.3 x 10(-5) microm(2)[(0-6.6) x 10(-5)/microm(2)] afterward (P > 0.05). For the proportion of NE-positive tumor, it was 7.0% (0%-14.9%) and 4.5% (0%-13.1%) (P > 0.05). No correlation existed between NE-differentiation and the neoadjuvant hormonal treatment. The NE cell density did not differ significantly between 12 non-/slightly regressive tumor foci and 6 highly regressive ones (P > 0.05).
CONCLUSIONShort-term neoadjuvant hormonal therapy does not induce clonal propagation of NE cells. The degree of tumor regression following short-term neoadjuvant hormonal therapy is not correlated with the NE differentiation.
